Background: Respiratory failure due to COVID-19 pneumonia is associated with high mortality and may overwhelm health care systems, due to the surge of patients requiring advanced respiratory support. Shortage of intensive care unit (ICU) beds required many patients to be treated outside the ICU despite severe gas exchange impairment. Helmet is an effective interface to provide continuous positive airway pressure (CPAP) noninvasively. We report data about the usefulness of helmet CPAP during pandemic, either as treatment, a bridge to intubation or a rescue therapy for patients with care limitations (DNI).
Methods: In this observational study we collected data regarding patients failing standard oxygen therapy (i.e., non-rebreathing mask) due to COVID-19 pneumonia treated with a free flow helmet CPAP system. Patients' data were recorded before, at initiation of CPAP treatment and once a day, thereafter. CPAP failure was defined as a composite outcome of intubation or death.
Results: A total of 306 patients were included; 42% were deemed as DNI. Helmet CPAP treatment was successful in 69% of the full treatment and 28% of the DNI patients (P < 0.001). With helmet CPAP, PaO/FiO ratio doubled from about 100 to 200 mmHg (P < 0.001); respiratory rate decreased from 28 [22-32] to 24 [20-29] breaths per minute, P < 0.001). C-reactive protein, time to oxygen mask failure, age, PaO/FiO during CPAP, number of comorbidities were independently associated with CPAP failure. Helmet CPAP was maintained for 6 [3-9] days, almost continuously during the first two days. None of the full treatment patients died before intubation in the wards.
Conclusions: Helmet CPAP treatment is feasible for several days outside the ICU, despite persistent impairment in gas exchange. It was used, without escalating to intubation, in the majority of full treatment patients after standard oxygen therapy failed. DNI patients could benefit from helmet CPAP as rescue therapy to improve survival.
Trial Registration: NCT04424992.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903369 | PMC |
| http://dx.doi.org/10.1186/s13054-021-03502-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Machine learning-based forecast of Helmet-CPAP therapy failure in Acute Respiratory Distress Syndrome patients.
Comput Methods Programs Biomed
December 2024
Politecnico di Milano, Dipartimento di Elettronica, Informazione e Bioingegneria, Piazza Leonardo Da Vinci 32, Milano, MI, 20133, Italy. Electronic address:
Background And Objective: Helmet-Continuous Positive Airway Pressure (H-CPAP) is a non-invasive respiratory support that is used for the treatment of Acute Respiratory Distress Syndrome (ARDS), a severe medical condition diagnosed when symptoms like profound hypoxemia, pulmonary opacities on radiography, or unexplained respiratory failure are present. It can be classified as mild, moderate or severe. H-CPAP therapy is recommended as the initial treatment approach for mild ARDS.
View Article and Find Full Text PDFCase report: Spontaneous arterial bleeding in the lateral thoracic region during helmet CPAP treatment: a report of three cases in patients with severe COVID-19.
Front Med (Lausanne)
November 2024
Unit of Anaesthesia and Intensive Care, Department of Human Pathology in Adulthood and Childhood, University of Messina, Messina, Italy.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has put enormous pressure on healthcare systems worldwide. While the majority of severe cases present with respiratory failure, thrombosis or bleeding have also been reported at unusual sites. Major bleeding, particularly in patients treated with therapeutic anticoagulation, has been observed between the second and third week after the onset of SARS-CoV-2 infection.
View Article and Find Full Text PDFCPAP delivered via a helmet interface in lightly sedated patients with moderate to severe ARDS: predictors of success outside the ICU.
J Bras Pneumol
December 2024
. Departamento de Medicina Interna, Universidade Federal do Ceará, Fortaleza (CE) Brasil.
Objective: This study aimed to describe the outcomes and explore predictors of intubation and mortality in patients with ARDS due to COVID-19 treated with CPAP delivered via a helmet interface and light sedation.
Methods: This was a retrospective cohort study involving patients with COVID-19-related ARDS who received CPAP using a helmet developed in Brazil (ELMO™), associated with a light sedation protocol in a pulmonology ward. Demographic, clinical, imaging, and laboratory data, as well as the duration and response to the ELMO-CPAP sessions, were analyzed.
Helmet Continuous Positive Airway Pressure for Acute Bronchiolitis Respiratory Failure in a Pediatric Ward: Is It a Replicable Experience?
Children (Basel)
October 2024
Emergency, Acceptance and General Pediatrics Department, Bambino Gesù Children's Hospital IRCCS, Piazza Sant'Onofrio 4, 00165 Rome, Italy.
(1) Background: Helmet Continuous Positive Airway Pressure (H-CPAP) has primarily been used in intensive care settings to treat moderate-to-severe bronchiolitis in infants. We aim to report on the feasibility of H-CPAP for selected infants with bronchiolitis in a pediatric ward. (2) Methods: A retrospective, observational, consecutive case series was studied of 26 patients who received H-CPAP on the pediatric ward from October 2022 to February 2023, including a description of patient outcomes and costs.
View Article and Find Full Text PDFOxygen therapy and noninvasive respiratory supports in acute hypoxemic respiratory failure: a narrative review.
Ann Intensive Care
October 2024
Assistance Publique - Hôpitaux de Paris, Hôpital Cochin, Service des Urgences, Université Paris-Cité, Paris, France.
Background: This narrative review was written by an expert panel to the members of the jury to help in the development of clinical practice guidelines on oxygen therapy.
Results: According to the expert panel, acute hypoxemic respiratory failure was defined as PaO < 60 mm Hg or SpO < 90% on room air, or PaO/FiO ≤ 300 mm Hg. Supplemental oxygen should be administered according to the monitoring of SpO, with the aim at maintaining SpO above 92% and below 98%.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!